Structure Therapeutics (NASDAQ:GPCR) Rating Increased to Sell at Wall Street Zen

Key Points

• Wall Street Zen upgraded Structure Therapeutics from “strong sell” to “sell,” while the broader analyst consensus remains “Moderate Buy” with an average price target of $110.91.
• Shares opened at $54.51, well below the 12-month high of $94.90. The company reported a quarterly loss of $0.49 per share, missing analyst expectations of a $0.39 loss.
• Institutional investors own approximately 91.78% of GPCR, with several funds recently initiating or increasing their positions.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) was upgraded by Wall Street Zen from a "strong sell" rating to a "sell" rating in a research note issued on Monday.

GPCR has been the topic of several other research reports. Citizens Jmp reduced their price objective on shares of Structure Therapeutics from $113.00 to $110.00 and set a "market outperform" rating on the stock in a research note on Friday, August 7th. Citigroup reiterated a "market outperform" rating on shares of Structure Therapeutics in a report on Friday, August 7th. HC Wainwright lowered their target price on Structure Therapeutics from $100.00 to $70.00 and set a "buy" rating for the company in a research note on Thursday, June 11th. Weiss Ratings restated a "sell (d-)" rating on shares of Structure Therapeutics in a report on Friday, July 17th. Finally, Canaccord Genuity Group set a $111.00 target price on shares of Structure Therapeutics in a report on Friday, August 7th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $110.91.

Structure Therapeutics Price Performance

Shares of NASDAQ:GPCR opened at $54.51 on Monday. The company's 50-day moving average price is $49.22 and its two-hundred day moving average price is $52.63. Structure Therapeutics has a 12 month low of $18.26 and a 12 month high of $94.90. The firm has a market cap of $3.79 billion, a P/E ratio of -54.51 and a beta of -1.43.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.10). As a group, equities analysts predict that Structure Therapeutics will post -1.84 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in GPCR. CWM LLC increased its stake in Structure Therapeutics by 35.2% during the 4th quarter. CWM LLC now owns 480 shares of the company's stock worth $33,000 after acquiring an additional 125 shares during the period. Sterling Capital Management LLC acquired a new position in Structure Therapeutics in the 1st quarter worth about $28,000. State of Wyoming bought a new position in Structure Therapeutics in the 2nd quarter valued at approximately $28,000. Police & Firemen s Retirement System of New Jersey acquired a new position in shares of Structure Therapeutics during the fourth quarter worth $127,000. Finally, Assetmark Inc. raised its position in Structure Therapeutics by 21.4% during the 1st quarter. Assetmark Inc. now owns 2,544 shares of the company's stock worth $123,000 after purchasing an additional 449 shares during the last quarter. 91.78% of the stock is owned by institutional investors.

Structure Therapeutics Company Profile

Structure Therapeutics NASDAQ: GPCR is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source